NCT02264821

Brief Summary

The aim of this study is to compare effective analgesia with continuous wound infiltration of ropivacaine through multi-holed catheter or with morphine 100 mcg added intrathecally to spinal anesthesia, after elective Caesarean delivery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
192

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Feb 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2014

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

August 25, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 15, 2014

Completed
8 months until next milestone

Results Posted

Study results publicly available

June 9, 2015

Completed
Last Updated

June 9, 2015

Status Verified

May 1, 2015

Enrollment Period

2.5 years

First QC Date

August 25, 2014

Results QC Date

April 22, 2015

Last Update Submit

May 21, 2015

Conditions

Keywords

analgesiacaesareanwound infiltrationintrathecal morphine.

Outcome Measures

Primary Outcomes (2)

  • Duration of Effective Analgesia

    T0 until first request of morphine PCAIV

    30 hours after spinal injection T0

  • Morphine Consumption

    Morphine consumption with PCAIV

    30 hours after spinal injection T0

Secondary Outcomes (1)

  • Incidence of Morphine Side Effects: Nausea, Vomiting, Pruritus.

    30 hours after spinal injection

Study Arms (3)

ropivacaine infiltration

EXPERIMENTAL

ropivacaine 2 mg/ml bolus 15 ml continuous 10 ml/h wound infusion and intrathecal saline

Drug: ropivacaine infiltration

rachi morphine

EXPERIMENTAL

100 µg intrathecal morphine and saline infiltration

Drug: intrathecal morphine

placebo

PLACEBO COMPARATOR

intrathecal saline and saline infiltration

Drug: placebo

Interventions

wound infiltration

Also known as: Naropin, local anesthetic
ropivacaine infiltration

100 µg added to the spinal anaesthesia

Also known as: spinal morphine
rachi morphine

placebo in spinal anaesthesia and in wound infiltration

Also known as: Nacl 0,9 %, saline solution
placebo

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 18 years and more, ASA 1 or ASA 2, pregnant with at least 34 weeks of gestational age, admitted for a planned caesarian with a Pfannenstiel incision and having signed the informed consent form.

You may not qualify if:

  • Refusal of the patient or contra-indication to locoregional anesthesia
  • Allergy to the products used
  • ASA 3
  • ASA 4
  • Sleep apnea syndrome and/or obesity (BMI \> 35)
  • Size inferior to 155cm
  • existence of a language barrier

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Universitaire Brugmann

Brussels, 1020, Belgium

Location

MeSH Terms

Conditions

Agnosia

Interventions

RopivacaineAnesthetics, LocalSaline Solution

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesAnestheticsCentral Nervous System DepressantsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesSensory System AgentsPeripheral Nervous System AgentsCentral Nervous System AgentsTherapeutic UsesCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Results Point of Contact

Title
Dr Madeleine Wilwerth
Organization
CHU Brugmann

Study Officials

  • Philippe Van der Linden, PhD, MD

    CHU Brugmann

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Primary Investigator

Study Record Dates

First Submitted

August 25, 2014

First Posted

October 15, 2014

Study Start

February 1, 2012

Primary Completion

August 1, 2014

Study Completion

August 1, 2014

Last Updated

June 9, 2015

Results First Posted

June 9, 2015

Record last verified: 2015-05

Locations